Firefly Neuroscience (AIFF) Common Equity (2010 - 2026)

Firefly Neuroscience has reported Common Equity for 17 years, with the latest figure at $14.7 million in Q2 2026.

• On a quarterly basis, Common Equity rose 21.18% year-over-year to $14.7 million in Q2 2026; TTM through Jun 2026 was $14.7 million, a 21.18% increase from a year earlier, with the FY2025 full-year figure at $7.6 million, up 2136.53% from the prior year.
• Common Equity was $14.7 million for Q2 2026 at Firefly Neuroscience, up from $8.4 million in the prior quarter.
• The five-year high for Common Equity was $15.7 million in Q1 2022, with the low at -$2.8 million in Q3 2024.
• Average Common Equity over 5 years is $5.2 million, with a median of $3.8 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 444.04% in 2024, then soared 57711.11% in 2025.
• Over 5 years, Common Equity stood at -$2.2 million in 2022, then surged by 104.9% to $109000.0 in 2023, then sank by 444.04% to -$375000.0 in 2024, then soared by 2136.53% to $7.6 million in 2025, then surged by 92.0% to $14.7 million in 2026.
• The last three Common Equity figures came in at $14.7 million (Q2 2026), $8.4 million (Q1 2026), and $7.6 million (Q4 2025), per Business Quant data.